Novavax (Novavax) Total Inventories

: $41.7 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Novavax's total inventories for the quarter that ended in Dec. 2023 was $41.7 Mil. Novavax's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $55.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Novavax's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-12.20.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Novavax's Days Inventory for the three months ended in Dec. 2023 was 32.76.

Inventory Turnover measures how fast the company turns over its inventory within a year. Novavax's Inventory Turnover for the quarter that ended in Dec. 2023 was 2.79.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Novavax's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.22.

Novavax Total Inventories Historical Data

The historical data trend for Novavax's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

8.87

36.68

41.70

Novavax Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories																36.68	34.19	23.49	69.59	41.70

Novavax Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Novavax (NAS:NVAX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Novavax's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(568.505	+	0.75 * 297.24	+	0.5 * 41.696	-	2514.417
-	0	-	0)	/	139.506
=	-12.20

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Novavax's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	55.644	/	154.976	*	365 / 4
	=	32.76

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Novavax's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	154.976	/	55.644
	=	2.79

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Novavax's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	55.644	/	253.399
	=	0.22

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Novavax Total Inventories Related Terms

Thank you for viewing the detailed overview of Novavax's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (Novavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Executives

Filip Dubovsky	officer: President, R&D	C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn	officer: President, R&D	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara	officer: EVP, Chief Strategy Officer	333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs	director, officer: President and CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii	officer: SVP, General Counsel	C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck	director, officer: President and CEO	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino	officer: SVP, CBO and CFO	9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly	officer: EVP, CFO and Treasurer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans	director	1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr	director	241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100